Physician profile
Robert K Matlack
NPI 1700881190
$2,914.92
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,152 · 2020: $188 · 2021: $634 · 2022: $847 · 2023: $93.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $93.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $93.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $392.11 | 2019-2022 | |
| Abbvie INC. | $236.22 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $233.36 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $231.19 | 2019-2022 | |
| Alkermes, INC. | $217.60 | 2020-2022 | |
| Tris Pharma INC | $193.05 | 2019-2022 | |
| Allergan, INC. | $177.76 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $160.32 | 2021 | |
| Neos Therapeutics, LP | $139.85 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $133.38 | 2019-2022 | |
| Lundbeck LLC | $125.58 | 2019-2023 | Rexulti |
| Neurocrine Biosciences, INC. | $87.84 | 2020-2022 | |
| Adlon Therapeutics L.P. | $81.23 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $74.79 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $67.44 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $48.27 | 2019-2022 | |
| Vertical Pharmaceuticals, LLC | $40.51 | 2019 | |
| Shire North American Group INC | $39.92 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $34.96 | 2021 | |
| Corium, LLC | $34.09 | 2022 | |
| Bausch Health US, LLC | $31.64 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $26.22 | 2021 | |
| Axsome Therapeutics, INC. | $24.57 | 2023 | Auvelity |
| Owp Pharmaceuticals, INC. | $19.00 | 2019 | |
| Eisai INC. | $15.43 | 2022 | |
| Rhodes Pharmaceuticals L.P. | $13.75 | 2019 | |
| Noven Therapeutics, LLC | $11.93 | 2022 | |
| Aytu Biopharma, INC. | $11.48 | 2021 | |
| Avanir Pharmaceuticals, INC. | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Matlack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.